# pharmaand GmbH clinical trials: 22 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 22 trials with pharmaand GmbH as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by pharmaand GmbH: 22 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/pharmaand-gmbh

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 22
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 22 newest of 22, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| December 21, 2020 | NCT04676334 | CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib | pharmaand GmbH | Phase 3 | Completed | Metastatic Castration-Resistant Prostate Cancer, Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer... | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04676334) |
| November 27, 2019 | NCT04179396 | Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP) | pharmaand GmbH | Phase 1 | Completed | Metastatic Castration Resistant Prostate Cancer | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04179396) |
| November 21, 2019 | NCT04171700 | A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes | pharmaand GmbH | Phase 2 | Terminated | Solid Tumor | 83 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04171700) |
| November 4, 2019 | NCT04150289 | A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat | pharmaand GmbH | Observational | Completed | Multiple Myeloma | 248 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04150289) |
| June 20, 2019 | NCT03992131 | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) | pharmaand GmbH | Phase 1/2 | Terminated | Ovarian Cancer, Triple-negative Breast Cancer, Urothelial Carcinoma, Solid Tumor | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03992131) |
| May 17, 2019 | NCT03954366 | Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives | pharmaand GmbH | Phase 1 | Completed | Neoplasms | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03954366) |
| January 31, 2019 | NCT03824704 | A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) | pharmaand GmbH | Phase 2 | Terminated | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, High Grade Serous Carcinoma... | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03824704) |
| May 11, 2018 | NCT03522246 | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line... | pharmaand GmbH | Phase 3 | Active not recruiting | Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Newly Diagnosed, FIGO Stage III-IV, Partial... | 1,097 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03522246) |
| May 11, 2018 | NCT03521037 | Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor | pharmaand GmbH | Phase 1 | Completed | Neoplasms | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03521037) |
| April 17, 2018 | NCT03499444 | A Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor | pharmaand GmbH | Phase 1 | Completed | Advanced Solid Tumor | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03499444) |
| January 12, 2018 | NCT03397394 | Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma | pharmaand GmbH | Phase 2 | Terminated | Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Renal Pelvis Carcinoma, Ureter Carcinoma... | 97 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03397394) |
| December 8, 2016 | NCT02986100 | Absorption, Metabolism, and Excretion Following a Single Oral Dose of \[14C\]-Rucaparib | pharmaand GmbH | Phase 1 | Completed | Solid Tumor | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02986100) |
| November 29, 2016 | NCT02975934 | A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and... | pharmaand GmbH | Phase 3 | Completed | Metastatic Castration Resistant Prostate Cancer | 405 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02975934) |
| November 2, 2016 | NCT02952534 | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency | pharmaand GmbH | Phase 2 | Completed | Metastatic Castration Resistant Prostate Cancer | 277 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02952534) |
| August 4, 2016 | NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | pharmaand GmbH | Phase 3 | Completed | Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer | 349 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02855944) |
| April 15, 2016 | NCT02740712 | Pharmacokinetic Drug-Drug Interaction Study of Rucaparib | pharmaand GmbH | Phase 1 | Completed | Neoplasms | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02740712) |
| January 13, 2016 | NCT02654990 | Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma | pharmaand GmbH | Phase 2 | Completed | Multiple Myeloma | 248 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02654990) |
| January 22, 2014 | NCT02042378 | A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation | pharmaand GmbH | Phase 2 | Completed | Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02042378) |
| October 23, 2013 | NCT01968213 | Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) | pharmaand GmbH | Phase 3 | Completed | Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer | 564 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01968213) |
| July 3, 2013 | NCT01891344 | A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal... | pharmaand GmbH | Phase 2 | Completed | Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer | 491 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01891344) |
| November 30, 2011 | NCT01482715 | A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) | pharmaand GmbH | Phase 1/2 | Completed | Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Advanced Solid Tumor With Evidence of Germline or Somatic BRCA | 136 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01482715) |
| November 6, 2009 | NCT01009190 | A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens | pharmaand GmbH | Phase 1 | Completed | Advanced Solid Tumors | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01009190) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 7 |
| Phase 1/2 | 2 |
| Phase 2 | 7 |
| Phase 3 | 5 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 17 |
| Terminated | 4 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Fallopian Tube Neoplasms | 8 |
| Ovarian Neoplasms | 7 |
| Carcinoma, Ovarian Epithelial | 5 |
| Recurrence | 4 |
| Neoplasms | 4 |
| Multiple Myeloma | 2 |
| Prostatic Neoplasms | 2 |
| Urinary Bladder Neoplasms | 2 |
| Carcinoma, Transitional Cell | 2 |
| Pancreatic Neoplasms | 2 |
| Genital Neoplasms, Male | 1 |
| Pathologic Complete Response | 1 |
| Ureteral Neoplasms | 1 |
| Urethral Neoplasms | 1 |
| Triple Negative Breast Neoplasms | 1 |
| Breast Neoplasms | 1 |
| Lung Neoplasms | 1 |
| Colonic Neoplasms | 1 |
| Stomach Neoplasms | 1 |
| Colorectal Neoplasms | 1 |
| Sarcoma | 1 |
| Neoplasm Metastasis | 1 |
| Esophageal Neoplasms | 1 |
| Leiomyosarcoma | 1 |
| Carcinosarcoma | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Vascular medicine practices in the United States](https://specstream.ai/data/businesses/vascular-medicine-practices/united-states)
- [Child care centers in the United States](https://specstream.ai/data/businesses/child-care-centers/united-states)
- [Home health care agencies in the United States](https://specstream.ai/data/businesses/home-health-care-agencies/united-states)
- [Plasterers in the United States](https://specstream.ai/data/businesses/plasterers/united-states)
- [Waterproofing contractors in the United States](https://specstream.ai/data/businesses/waterproofing-contractors/united-states)
- [Commercial printers in the United States](https://specstream.ai/data/businesses/commercial-printers/united-states)
